REGENERON 2025 – REVENUES UP, DUPIXENT SALES SOAR

By Chris Stiles • Sunday, February 01 04:19 • Permanent Link

Regeneron Pharmaceuticals, Inc. has reported its financial and operating results for the fourth quarter and full year of 2025. Here are the key facts and figures from the press release:

Total revenues for the fourth quarter of 2025 increased by 3% to $3.9 billion compared to the fourth quarter of 2024. For the full year 2025, total revenues increased by 1% to $14.3 billion versus 2024.
Dupixent® global net sales (recorded by Sanofi) increased significantly, with a 34% increase to $4.9 billion in the fourth quarter of 2025 compared to the same period in 2024. Full year 2025 dupixent global net sales increased by 26% to $17.8 billion versus 2024.
Eylea HD® U.S. net sales saw a remarkable 66% increase to $506 million in the fourth quarter of 2025, and a 36% increase to $1.6 billion for the full year 2025.
GAAP earnings per share (EPS) for the fourth quarter of 2025 were $7.86, while non-GAAP EPS was $11.44. This includes an unfavorable impact from an acquired charge.
The company's research and development (R&D) expenses increased by 15% to $1.626 billion in the fourth quarter of 2025 compared to the same period in 2024. For the full year 2025, R&D expenses were $5.85 billion, a 14% increase over 2024.
Acquired in-process research and development (IPR&D) expenses for the full year 2025 included an $80 million up-front payment in connection with the company's license agreement with Hansoh Pharmaceuticals Group Company Limited.
Other financial highlights include increases in collaboration revenue from Sanofi, which was $1.64 billion in the fourth quarter of 2025, a 35% increase over the same period in 2024.

These figures showcase the company's solid financial performance, driven by the success of its blockbuster medicines and significant growth in key product sales. Regeneron's investments in research and development have also led to notable pipeline advances. As a result of these announcements, the company's shares have moved -1.2% on the market, and are now trading at a price of $733.04. Check out the company's full 8-K submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.